Investigation Report on China Sodium Ibandronate Market, 2010-2019
|出版商||China Research and Intelligence||商品編碼||333635|
|出版日期||內容資訊||英文 30 Pages
|Sodium Ibandronate的中國市場分析 Investigation Report on China Sodium Ibandronate Market, 2010-2019|
|出版日期: 2015年06月25日||內容資訊: 英文 30 Pages||
中國國內每年產生300萬人以上的新癌症患者，其中約50％為骨轉移性癌症的患者。Sodium Ibandronate是1996年在德國和奧地利認證的抗骨轉移性癌症藥物，經過更方便的投藥法的開發，2005年也受美國認證。Sodium Ibandronate到近幾年，在中國國內急速擴大其年度銷售額，2010年達5038萬人民幣，2014年達8723萬人民幣，以年複合成長率(CAGR) 14.71％的速度成長。
Bone metastasis is common in patients with advanced malignant tumor. According to the statistics, each year millions of tumor patients especially patients with breast cancer, prostate cancer and lung cancer suffer from bone metastasis around the world. Bone metastasis of malignant tumor often result in severe lesions in bone including such skeletal-related events as bone pain, pathological fracture, spinal cord compression and hypercalcemia. Once Bone metastasis occurs, most patients will suffer from different degrees of pain even pathological fracture, which will obviously influence their life quality.
The most common drug for bone metastasis is diphosphonate. Three generations of diphosphonate, respectively, etidronate and clodronate representated by Bonefos, pamidronate and alendronate sodium represented by Bonin as well as sodium ibandronate and zoledronic acid are now used in the clinic.
First registered and used in the clinic under the trade name of Bondronat in Germany and Austria in 1996, sodium ibandronate was approved by FDA to come into the market as a daily treatment of osteoporosis under the trade name of Boniva. However, since drug makers later developed more convenient dose, Boniva has not appeared in the American market until FDA approved its monthly use in 2005.
The number of new cases of cancer is over 3 million each year in China, among which about 50% suffer from bone metastasis. In 2001, some local enterprises began to apply for relevant products of sodium ibandronate and succeeded in 2002. In Jul. 2006, sodium ibandronate produced by Roche entered China under the trade name of Bondronat. Since then, sodium ibandronate has developed fast, annual sales value rising from CNY 50.38 million in 2010 to CNY 87.23 million in 2014 and CAGR during this period reaching up to 14.71%. Sodium ibandronate enjoys a vast demand in China. Currently, sodium ibandronate market in China is mainly occupied by the following companies: Science & Technology General Company Hebei Medical University, Roche Diagnostics GmbH GE), Hencer Pharmacy and Easton Pharmaceutical Co., Ltd, among which Science & Technology General Company Hebei Medical University has the largest market share of about 58% for sales value in 2014.
With the degradation of environmental pollution and the ageing population, the number of new cases of cancer each year is expected to keep increasing, which shall boost the growth of sodium ibandronate market in China.
Readers can get at least the following information from this report:
The author suggests the following groups of people purchase this report: